Is Rigel Pharmaceuticals, Inc. (RIGL) a Buy, Sell, or Hold?
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$41.17 USD
-$0.13 (-0.31%)
- Volume
- 271.75K
- Average Volume
- 400.07K
- Market Capitalization
- $761.73M
- P/E Ratio
- 2.05
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $52.24
- Year Low
- $18.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.62
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Raul R. Rodriguez |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RIGL |
| CUSIP | 766559702 |
| CIK | 0001034842 |
| Web | https://www.rigel.com |
| Phone | 650 624 1100 |
| Currency | USD |
| Employees | 172 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.62 |
| Quick Ratio | 2.48 |
| Cash Ratio | 0.27 |
Sales & Book Value
| Annual Sales | $294.28M |
| Price / Sales | 2.54 |
| Cash Flow | 4.31 |
| Price / Cash Flow | 9.61 |
| Price / Book | 1.90 |
Price Target and Rating
| Average Stock Price Forecast | $38.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | 8.34% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $19.48 |
| Trailing P/E Ratio | 2.05 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $367.02M |
| Net Margin | 121.51% |
| Pretax Margin | 40.69% |
| Return on Equity | 147.03% |
| Return on Assets | 72.18% |
Financials Score
| AltmanZ Score | 3.34 |
| Piotroski Score | 6.00 |
| Working Capital | 144.54M |
| Total Assets | 504.61M |
| Ebit | 128.87M |
| Market Cap | 764.14M |
| Total Liabilities | 104.71M |
Poll Results
About Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric pa ... tients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-07 08:05:00
SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Appoints Board Member Alison L. Hannah, M.D.
2026-07-01 08:05:00
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L.
A Look At The Transformation Around Rigel Pharmaceuticals
2026-06-20 07:44:13
Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million.
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
2026-06-16 16:01:00
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions.
Rigel to Present at the Jefferies Global Healthcare Conference
2026-05-27 08:05:00
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m.
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
2026-05-21 17:17:00
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session Real-world data further supports the use of REZLIDHIA ® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax SOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 29, 2026.
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-14 08:05:00
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m.
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
2026-05-12 23:10:43
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Frequently Asked Questions
-
What is the current Rigel Pharmaceuticals, Inc. (RIGL) stock price?
-
Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL) stock price is $41.17 in the last trading session. During the trading session, RIGL stock reached the peak price of $52.24 while $18.66 was the lowest point it dropped to. The percentage change in RIGL stock occurred in the recent session was --0.31% while the dollar amount for the price change in RIGL stock was -$-0.13.
-
RIGL's industry and sector of operation?
-
The NASDAQ listed RIGL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RIGL?
-
Alison L. Hannah | Executive Vice President & Chief Medical Officer
Lisa Rojkjaer | Executive Vice President & Chief Medical Officer
David A. Santos | Executive Vice President & Chief Commercial Officer
Dean L. Schorno | Executive Vice President & Chief Financial Officer
Joseph Lasaga | Executive Vice President & Chief Business Officer -
How many employees does RIGL have?
-
Number of RIGL employees currently stands at 172. RIGL operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
Link for RIGL official website?
-
Official Website of RIGL is: https://www.rigel.com
-
How do I contact RIGL?
-
RIGL could be contacted at phone #650 624 1100 and can also be accessed through its website. RIGL operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
How many shares of RIGL are traded daily?
-
The average number of RIGL shares traded daily for last 3 months was 400.07K.
-
What is the market cap of RIGL currently?
-
The market value of RIGL currently stands at $761.73M with its latest stock price at $41.17